December 3, 2019
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition.
The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
The poster is being shown on Saturday, December 7, from 5:30 PM to 7:30 PM at Hall B, Level 2 of Orange County Convention Center:
“A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies”
by Srikumar Sahasranaman (Clinical Pharmacology, BeiGene USA, Inc.), Oleg Demin Jr (InSysBio), Dmitry Shchelokov (InSysBio), Veronika Musatova (InSysBio), Nageshwar Budha (Clinical Pharmacology, BeiGene USA, Inc.) and Ying Ou (Clinical Pharmacology, BeiGene USA, Inc.).
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | March 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Mar 2020 12:25
13th InSysBio Annual Internal Scientific Meeting
26-28 February 2020 InSysBio QSP-company held its 13th Annual Internal Scientific Meeting. InSysBio team presented the results of 2019 year professional progress. Every member demonstrated their personal achievements and shared the plans for the future development. Oleg Demin, InSysBio CEO and founder, summarized all the company’s advancement of the year 2019.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
1.
10 Mar 2020 12:48
InSysBio to share the news from QSPC2020 management
Today we have received the concerning news from QSPC2020 organizers about the cancellation of the conference in response to COVID-19 outbreak continuation. Quantitative Systems Pharmacology Conference 2020 was planned to be held in April 22-24, 2020 Leiden, The Netherlands. InSysBio team was prepared to present 10 posters
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
